Multicenter prospective trial after first unsuccesful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of nilotinib in inducing the persistance of molecular remission after stopping tyrosine kinase inhibitors a second time or 3rd time
Latest Information Update: 12 Sep 2023
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms NAUT
- 04 Nov 2021 Planned End Date changed from 1 Sep 2026 to 1 Sep 2027.
- 04 Nov 2021 Planned primary completion date changed from 1 Sep 2025 to 1 Sep 2026.
- 04 Nov 2021 Status changed from recruiting to active, no longer recruiting.